Product overview

  • Name
  • Short description
    mTOR inhibitor and potent immunosuppressant
  • Biological description

    mTOR inhibitor and potent immunosuppressant.

    Complexes with FKBP12 to bind mTORC1 to inhibit mTOR activity and block subsequent activation of p70 s6 kinase (IC50 = 50 pM).

    Induces autophagy and apoptosis.

    Promotes hPSC differentiation to blood progenitor and mesendoderm cells.

    Rapamycin can also be used in inducible CRISPR/Cas9 systems to enable inducible gene editing.

    Active in vivo.

  • Alternative names
  • Biological action
  • Mode of action
    interferes with protien synthesis by enzyme inhibition
  • Antibiotic Spectrum
    yeast and fungi
  • Purity
  • Our products in action


  • Chemical name
  • Molecular Weight
  • Molecular Formula
  • CAS Number
  • PubChem identifier
  • InChiKey
  • MDL number
  • Appearance
    White to off-white

Storing and Using Your Product

  • Storage instructions
    -20 °C;
  • Solubility overview
    Soluble in ethanol (20 mM) and DMSO (50 mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for Rapamycin

  • Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.

    Kobayashi et al (2007) Cancer Sci 98(5) : 726-33
    PubMedID: 17425689
  • Rapamycins: mechanism of action and cellular resistance.

    Huang et al (2003) Cancer Biol Ther 2(3) : 222-32
    PubMedID: 12878853
  • Chemical modulators of autophagy as biological probes and potential therapeutics.

    Flemin et al (2011) Nat Chem Biol 7(1) : 9-17
    PubMedID: 21164513
  • A split-Cas9 architecture for inducible genome editing and transcription modulation.

    Zetsche et al (2015) Nat Biotechnol 33(2) : 139-42
    PubMedID: 25643054